Updated Overall Survival (OS) Data from a Phase 3 Trial of Ipilimumab (Ipi) vs. Placebo in Men Post Chemotherapy

In a poster presentation at the recent European Society of Medical Oncologists (ESMO) there was a very interesting poster presented updating a phase 3 clinical trial (CA184-043) which evaluated the overall survival (OS) with radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. This trial did not meet its endpoint [...]

A Magic Bullet To Cure Cancer – Sorry, Not Yet – But Who Knows

So, you say that there is a magic bullet! A drug that will cure all types of cancer! Come on, lets get real, NO, it is not true, At Least Not Yet. I don’t usually comment on early stage (animal model) research because we simply are not rats, zebra fish, dogs or monkeys. This, I [...]

Dendreon Announces Data Presentations and Webcast on their Experimental Immunotherapy Provenge

Press Release: Dendreon Corporation (Nasdaq: DNDN) announced the following data presentations taking place at the American Urological Association's (AUA) Annual Meeting in Chicago, as well as a Dendreon-sponsored IMPACT data webcast conference call: (for those of us who will be unable to attend the session at AUA in Chicago) April 28, 2009, 2:20 p.m. CDT-"A [...]